The ORL-1 receptor system: Are there opportunities for antagonists in pain therapy?

Beatriz Fioravanti, Todd W Vanderah

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Following the cloning of the classical opioid receptors (μ, δ and κ), the opioid receptor like-1 (ORL-1) was identified as a G-protein coupled receptor (GPCR) with 65% structure homology to the other members of the opioid family. Its endogenous ligand nociception/ orphanin FQ (N/ OFQ) was discovered shortly thereafter, becoming the subject of investigation in numerous studies. Since activation of the ORL-1 receptor by N/OFQ leads to G i-coupling and signal transduction similar to that of opioid receptors, N/OFQ was thought to have a role in pain modulation, similar to that of the endogenous opioids. Surprisingly, studies characterizing N/OFQ's effects on pain transmission yielded conflicting results, attributing to N/OFQ both pronociceptive and antinociceptive actions, depending on doses and routes of administration as well as species and sex of the subjects. With the development of selective and potent ORL-1 antagonists, many scientists believed these contradicting actions would be elucidated. Here we review the recent literature reporting the use of novel ORL-1 antagonists, both peptide and non-peptide, in different models of pain and discuss their use as research tools or potential drug candidates.

Original languageEnglish (US)
Pages (from-to)1442-1451
Number of pages10
JournalCurrent Topics in Medicinal Chemistry
Volume8
Issue number16
DOIs
StatePublished - 2008

Fingerprint

Opioid Receptors
Pain
Opioid Analgesics
Therapeutics
Nociception
G-Protein-Coupled Receptors
Organism Cloning
Signal Transduction
Ligands
Peptides
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Drug Discovery

Cite this

The ORL-1 receptor system : Are there opportunities for antagonists in pain therapy? / Fioravanti, Beatriz; Vanderah, Todd W.

In: Current Topics in Medicinal Chemistry, Vol. 8, No. 16, 2008, p. 1442-1451.

Research output: Contribution to journalArticle

@article{4f9c005b273a42b0a034eb28a3da37df,
title = "The ORL-1 receptor system: Are there opportunities for antagonists in pain therapy?",
abstract = "Following the cloning of the classical opioid receptors (μ, δ and κ), the opioid receptor like-1 (ORL-1) was identified as a G-protein coupled receptor (GPCR) with 65{\%} structure homology to the other members of the opioid family. Its endogenous ligand nociception/ orphanin FQ (N/ OFQ) was discovered shortly thereafter, becoming the subject of investigation in numerous studies. Since activation of the ORL-1 receptor by N/OFQ leads to G i-coupling and signal transduction similar to that of opioid receptors, N/OFQ was thought to have a role in pain modulation, similar to that of the endogenous opioids. Surprisingly, studies characterizing N/OFQ's effects on pain transmission yielded conflicting results, attributing to N/OFQ both pronociceptive and antinociceptive actions, depending on doses and routes of administration as well as species and sex of the subjects. With the development of selective and potent ORL-1 antagonists, many scientists believed these contradicting actions would be elucidated. Here we review the recent literature reporting the use of novel ORL-1 antagonists, both peptide and non-peptide, in different models of pain and discuss their use as research tools or potential drug candidates.",
author = "Beatriz Fioravanti and Vanderah, {Todd W}",
year = "2008",
doi = "10.2174/156802608786264227",
language = "English (US)",
volume = "8",
pages = "1442--1451",
journal = "Current Topics in Medicinal Chemistry",
issn = "1568-0266",
publisher = "Bentham Science Publishers B.V.",
number = "16",

}

TY - JOUR

T1 - The ORL-1 receptor system

T2 - Are there opportunities for antagonists in pain therapy?

AU - Fioravanti, Beatriz

AU - Vanderah, Todd W

PY - 2008

Y1 - 2008

N2 - Following the cloning of the classical opioid receptors (μ, δ and κ), the opioid receptor like-1 (ORL-1) was identified as a G-protein coupled receptor (GPCR) with 65% structure homology to the other members of the opioid family. Its endogenous ligand nociception/ orphanin FQ (N/ OFQ) was discovered shortly thereafter, becoming the subject of investigation in numerous studies. Since activation of the ORL-1 receptor by N/OFQ leads to G i-coupling and signal transduction similar to that of opioid receptors, N/OFQ was thought to have a role in pain modulation, similar to that of the endogenous opioids. Surprisingly, studies characterizing N/OFQ's effects on pain transmission yielded conflicting results, attributing to N/OFQ both pronociceptive and antinociceptive actions, depending on doses and routes of administration as well as species and sex of the subjects. With the development of selective and potent ORL-1 antagonists, many scientists believed these contradicting actions would be elucidated. Here we review the recent literature reporting the use of novel ORL-1 antagonists, both peptide and non-peptide, in different models of pain and discuss their use as research tools or potential drug candidates.

AB - Following the cloning of the classical opioid receptors (μ, δ and κ), the opioid receptor like-1 (ORL-1) was identified as a G-protein coupled receptor (GPCR) with 65% structure homology to the other members of the opioid family. Its endogenous ligand nociception/ orphanin FQ (N/ OFQ) was discovered shortly thereafter, becoming the subject of investigation in numerous studies. Since activation of the ORL-1 receptor by N/OFQ leads to G i-coupling and signal transduction similar to that of opioid receptors, N/OFQ was thought to have a role in pain modulation, similar to that of the endogenous opioids. Surprisingly, studies characterizing N/OFQ's effects on pain transmission yielded conflicting results, attributing to N/OFQ both pronociceptive and antinociceptive actions, depending on doses and routes of administration as well as species and sex of the subjects. With the development of selective and potent ORL-1 antagonists, many scientists believed these contradicting actions would be elucidated. Here we review the recent literature reporting the use of novel ORL-1 antagonists, both peptide and non-peptide, in different models of pain and discuss their use as research tools or potential drug candidates.

UR - http://www.scopus.com/inward/record.url?scp=58149192137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149192137&partnerID=8YFLogxK

U2 - 10.2174/156802608786264227

DO - 10.2174/156802608786264227

M3 - Article

C2 - 18991730

AN - SCOPUS:58149192137

VL - 8

SP - 1442

EP - 1451

JO - Current Topics in Medicinal Chemistry

JF - Current Topics in Medicinal Chemistry

SN - 1568-0266

IS - 16

ER -